Zongertinib clinical trials
Also written Hernexeos® and BI 1810631.
How each study uses zongertinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the zongertinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 8 Aug 2025 · HERNEXEOS · NDA 219042 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2024 (5); 1 more planned to start later
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 4 |
| 2024 | 5 |
| 2025 | 1 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 2
Boehringer Ingelheim (15) · M.D. Anderson Cancer Center (1) · MedSIR (1)
Often tested with
Tested in the same studies.
Bosentan (1) · Furosemide (1) · Zanidatamab (1) · Pembrolizumab (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 1 in phase 3
Studies that test zongertinib, phase 3 first.
- Dec 2026Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard TreatmentPhase 3 · Boehringer Ingelheim
- Dec 2026A Study in Healthy People to Test How Zongertinib is Taken up in the Body When Given as Tablets Made by Two Different Manufacturers With or Without FoodPhase 1 · Boehringer Ingelheim
- Aug 2027Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without PembrolizumabPhase 2 · Boehringer Ingelheim
Studies
Open first, then newest update. How each study uses zongertinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)RecruitingPhase 1Boehringer IngelheimNCT04886804Written as zongertinib
- Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 AlterationsRecruitingPhase 2Boehringer IngelheimNCT06581432Written as Zongertinib
- Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without PembrolizumabRecruitingPhase 2Boehringer IngelheimNCT07486817Written as Zongertinib
- Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadRecruitingPhase 1/2Boehringer IngelheimNCT06324357Written as Zongertinib
- Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsRecruitingPhase 3Boehringer IngelheimNCT07195695Written as Zongertinib
- A Phase 1a/1b Of Zanidatamab In Combination With Zongertinib In HER2-Mutated Non-Small Cell Lung Cancer (NSCLC)Not yet recruitingPhase 1M.D. Anderson Cancer CenterNCT07899801Written as Zongertinib
- A Study in Healthy People to Test How Zongertinib is Taken up in the Body When Given as Tablets Made by Two Different Manufacturers With or Without FoodRecruitingPhase 1Boehringer IngelheimNCT07789028Written as Zongertinib, Formulation A, reference product
- A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations.Not yet recruitingPhase 2MedSIRNCT07619066Written as Zongertinib (BI 1810631)
- A Study to Test How Zongertinib is Taken up in the Blood of People With and Without Liver ProblemsCompletedPhase 1Boehringer IngelheimNCT06692322Written as Zongertinib
- Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard TreatmentActive, not recruitingPhase 3Boehringer IngelheimNCT06151574Written as zongertinib
- A Study in Healthy Men to Test How Bosentan Influences the Amount of Zongertinib in the BloodCompletedPhase 1Boehringer IngelheimNCT07649941Written as Zongertinib
- A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the BloodCompletedPhase 1Boehringer IngelheimNCT06504862Written as Zongertinib
- A Study in Healthy Men to Test Whether Zongertinib Affects How 3 Other Medicines (Midazolam, Omeprazole, and Repaglinide) Are Taken up and Processed by the BodyCompletedPhase 1Boehringer IngelheimNCT06494761Written as zongertinib
- A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of Zongertinib in the BloodCompletedPhase 1Boehringer IngelheimNCT06028464Written as Zongertinib
- A Study in Healthy Men to Test How Zongertinib (BI 1810631) is Taken up and Processed by the BodyCompletedPhase 1Boehringer IngelheimNCT05879991Written as zongertinib (C-14)
- A Study in Healthy Men to Test How Itraconazole Influences the Amount of Zongertinib (BI 1810631) in the BloodCompletedPhase 1Boehringer IngelheimNCT05833139Written as Zongertinib
- A Study in Healthy Men to Test How Zongertinib is Taken up in the Body When Taken With or Without FoodCompletedPhase 1Boehringer IngelheimNCT06075277Written as zongertinib
Given beside what is tested · 1 — zongertinib is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
Results posted1
Newly registered1
Codes
What other systems call zongertinib · ClinicalTrials.gg INT002153
- MeSH (NLM) C000731876zongertinibOne source NLM
- UNII (FDA) DRH7R67UVLZONGERTINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q135706605zongertinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C199022ZongertinibOne source FDA
- DrugBank DB18762One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731876 | zongertinib | One source NLM |
| UNII (FDA) | DRH7R67UVL | ZONGERTINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q135706605 | zongertinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C199022 | Zongertinib | One source FDA |
| DrugBank | DB18762 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.